<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>measures | Dan W Joyce</title>
    <link>/tag/measures/</link>
      <atom:link href="/tag/measures/index.xml" rel="self" type="application/rss+xml" />
    <description>measures</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Thu, 18 Apr 2019 19:47:56 +0100</lastBuildDate>
    <image>
      <url>/media/icon_hub05f02e644906e3d80c1c494250cac2e_12120_512x512_fill_lanczos_center_2.png</url>
      <title>measures</title>
      <link>/tag/measures/</link>
    </image>
    
    <item>
      <title>Alternatives to Percentage Change</title>
      <link>/post/2021-05-23-symm-percent/add_symm_change_score/</link>
      <pubDate>Thu, 18 Apr 2019 19:47:56 +0100</pubDate>
      <guid>/post/2021-05-23-symm-percent/add_symm_change_score/</guid>
      <description>&lt;p&gt;The motivation for looking at this topic was primarily my naivety and
getting counter-intuitive results when I was looking at serial measures
of response to treatment. In particular, I wanted to use outcome
measures based on published conventions in the literature for threshold
response (the problems with this approach are a topic for another day).
I found some pointers on Frank Harrell&amp;rsquo;s blog on the topic of
&lt;a href=&#34;http://www.fharrell.com/post/percent/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;percentages&lt;/a&gt;, which mirrored
some of the discussion in Chapter 8 of (Senn 2008) which looks at
assumptions of additvity in treatment effects.&lt;/p&gt;
&lt;p&gt;Here&amp;rsquo;s the context in clinical trials in psychiatry: To define a
clinically-meaningful outcome (e.g. to a treatment/intervention) the
literature frequently uses &lt;em&gt;percentage change from baseline&lt;/em&gt; &amp;ndash; for
example (Leucht et al. 2009; Munk-Jørgensen 2011) in the context of
PANSS scores in psychosis. I&amp;rsquo;ll avoid the debate about why this may not
be appropriate for statistical modelling (e.g. using change from
baseline severity rather than using the baseline as a covariate in a
statistical model).&lt;/p&gt;
&lt;p&gt;To make this concrete, let A be the first measurement, and B the second
(i.e. pre-treatment and post-treatment respectively, or baseline and
endpoint). Leaving aside the correction to ensure minimum symptoms
severity is 0, Leucht&amp;rsquo;s formula for &lt;strong&gt;percentage reduction from baseline
PANSS&lt;/strong&gt; is essentially:&lt;/p&gt;
&lt;p&gt;$$
100 \times \frac{A - B}{A}
$$&lt;/p&gt;
&lt;p&gt;To make the example concrete, one of the criteria for defining
treatment resistance in schizophrenia (Howes et al. 2016) is: &amp;ldquo;&lt;strong&gt;less
than 20% symptom reduction during a prospective trial&lt;/strong&gt;&amp;rdquo; (of treatment)
using Leucht &lt;em&gt;et al&lt;/em&gt;&amp;rsquo;s formula (above). Re-wording this (to make it
compatible with Leucht): failure of a treatment trial is that the
&lt;strong&gt;percentage reduction from baseline is less than 20%&lt;/strong&gt;.&lt;/p&gt;
&lt;h1 id=&#34;percentages&#34;&gt;Percentages&lt;/h1&gt;
&lt;p&gt;The obvious reason for favouring percentage change from baseline is that
improvement (or worsening) is relative the patient&amp;rsquo;s initial level of
symptom severity. Assuming higher scores represents higher symptom
burden, a patient moving from a baseline A = 97 to an endpoint B = 77
represents a 20% change for that patient. A patient starting from a more
modest symptom burden, say A = 65, improving to B = 52 similarly
represents a 20% improvement.&lt;/p&gt;
&lt;p&gt;However, percentages are not &lt;strong&gt;symmetric&lt;/strong&gt; &amp;ndash; for example, if the first
measurement is A = 97, and the second (post-treatment) improved score is
B = 67 we have a &lt;strong&gt;percentage reduction&lt;/strong&gt; of
$$
100 \times \frac{97-67}{97} \approx 31 \%
$$&lt;/p&gt;
&lt;p&gt;Switching this around, for another patient who gets &lt;strong&gt;worse&lt;/strong&gt; by exactly
the same absolute amount after treatment: A = 67 and B = 97, yields
$$
100 \times \frac{67-97}{67} \approx -45 \%
$$&lt;/p&gt;
&lt;p&gt;Notice that both the sign and magnitude of the change are different,
but the absolute change in units is 30 in both cases.&lt;/p&gt;
&lt;p&gt;The next problem &amp;ndash; percentages are not &lt;strong&gt;additive&lt;/strong&gt;; assume a 30%
&lt;strong&gt;improvement&lt;/strong&gt; from an initial score of A = 100 &amp;ndash; the endpoint
(post-treatment) would be B = 70:&lt;/p&gt;
&lt;p&gt;$$
100 \times \frac{100 - 70}{100} = 30\%
$$&lt;/p&gt;
&lt;p&gt;Now assume we follow the same patient from B to another time point, C,
and they&amp;rsquo;ve gotten worse, returning to their baseline of 100:
$$
100 \times \frac{70 - 100}{70} \approx -42.9\%
$$&lt;/p&gt;
&lt;p&gt;On absolute scale units we have a series of measurements A = 100, B =
70 and C = 100, but we have seen a percentage change of 30% (A to B)
followed by a percentage change of -42.9% (B to C) despite A = C. In
other words, if we take the baseline A, add the change from A to B and
the change from B to C, we should have &lt;strong&gt;zero net change&lt;/strong&gt; from the
baseline, A to the last measurement C:&lt;/p&gt;
&lt;p&gt;$$
\begin{aligned}
A + (A-B) + (B-C) &amp;amp;= 100 + (100 - 70) + (70 - 100) \\\&lt;br&gt;
&amp;amp;= 100 + 30 - 30 \\\&lt;br&gt;
&amp;amp;= 100
\end{aligned}
$$
But if we use percentages, this is not the case; assuming that A
represents 100% &amp;ndash; the baseline level of symptom severity &amp;ndash; and abusing
notation, we let (A-B) stand for the percentage change from A to B, and
similarly for (B-C):
$$
\begin{aligned}
A + (A-B) + (B-C) &amp;amp;= 100 + 30 - 42.9 \\\&lt;br&gt;
&amp;amp;= 87.1\%
\end{aligned}
$$
Percentage change from baseline is intuitive because it allows for a
familiar and uniform representation of change &lt;em&gt;relative&lt;/em&gt; to the
patient&amp;rsquo;s baseline, but it&amp;rsquo;s counter-intuitive because it is asymmetric
and non-additive.&lt;/p&gt;
&lt;p&gt;Here&amp;rsquo;s a graphical representation: let the baseline (A) and endpoint (B)
values range from 0 to 100 respectively &amp;ndash; the interactive graph below
shows the behaviour of percentage change as both A and B vary:&lt;/p&gt;
&lt;iframe width=&#34;900&#34; height=&#34;800&#34; frameborder=&#34;0&#34; scrolling=&#34;no&#34; src=&#34;//plot.ly/~danwjoyce/11.embed&#34;&gt;&lt;/iframe&gt;
&lt;h1 id=&#34;sympercent&#34;&gt;Sympercent&lt;/h1&gt;
&lt;p&gt;The idea proposed in (Cole 2000), neatly illustrated in (T. J. Cole and
Altman 2017b; T. J. Cole and Altman 2017a) is to exploit a property of
natural logarithms where because
$$
\ln(A)−\ln(B)=\ln(A/B)
$$
the ratio A divided by B can be expressed as a sum, retaining
additivity and symmetry, and it turns out, approximating a &amp;lsquo;percentage&amp;rsquo;
change. The proposed name for this measure is &amp;ldquo;sympercent&amp;rdquo; and (Cole
2000) gave it the symbol &lt;strong&gt;s%&lt;/strong&gt; and the formula
$$
100 × [\ln(A)−\ln(B)]
$$
Repeating the examples above; first of all A = 97, B = 67 which gave
us a 31% (percent) improvement instead gives us the sympercent change:&lt;/p&gt;
&lt;p&gt;$$
100 × [\ln(97)−\ln(67)] ≈ 37 s\%
$$&lt;/p&gt;
&lt;p&gt;A different numerical value (37, versus 31). Note, however, that we
gain symmetry &amp;ndash; so with A = 67 and B = 97 (worsening symptoms from A to
B):&lt;/p&gt;
&lt;p&gt;$$
100 × [\ln(67)−\ln(97)] ≈ −37 s\%
$$&lt;/p&gt;
&lt;p&gt;The magnitude is the same (37) but the sign changes to represent
worsening, rather than improvement.&lt;/p&gt;
&lt;p&gt;Repeating the additivity example; improvement from A = 100 to B = 70 but
with subsequent worsening back to C = 100. We&amp;rsquo;ll drop the factor of 100
to simplify presentation:
$$
\begin{aligned}
\ln(A) + \big[ \ln(A)-\ln(B) \big] + \big[\ln(B)-\ln(C) \big] &amp;amp;= 4.61 + 0.36 - 0.36  \\\&lt;br&gt;
&amp;amp;= 4.61
\end{aligned}
$$&lt;/p&gt;
&lt;p&gt;That is, a net change of zero from the baseline.&lt;/p&gt;
&lt;p&gt;Switching to an alternative representation affords a more interpretable
and intuitive measure of change that preserves the idea of change
&lt;strong&gt;relative&lt;/strong&gt; to the patient&amp;rsquo;s baseline.&lt;/p&gt;
&lt;p&gt;Below, the behaviour of sympercent is shown over the range [0,100],
analogous to the percent change shown above:&lt;/p&gt;
&lt;iframe width=&#34;900&#34; height=&#34;800&#34; frameborder=&#34;0&#34; scrolling=&#34;no&#34; src=&#34;//plot.ly/~danwjoyce/13.embed&#34;&gt;&lt;/iframe&gt;
&lt;h1 id=&#34;the-original-problem&#34;&gt;The Original Problem&lt;/h1&gt;
&lt;p&gt;Let&amp;rsquo;s apply the &amp;lsquo;sympercent&amp;rsquo; idea for the problem originally introduced
&amp;ndash; a threshold of 20% improvement for symptoms.&lt;/p&gt;
&lt;p&gt;To simplify presentation, we drop the factor 100 and instead, work in
fractions of 1 (i.e. rather 20% we say 0.2 or 1/5). If we require at
least a 20% reduction in symptom scores to qualify as a response, then
we are saying:&lt;/p&gt;
&lt;p&gt;$$
\begin{aligned}
\frac{A-B}{A} &amp;amp;= 0.2 \\\&lt;br&gt;
A-B &amp;amp;= 0.2 \times A
\end{aligned}
$$
i.e. the difference between symptom scores at time points A and B
should be a fraction (0.2, or one-fifth) of the baseline A:&lt;/p&gt;
&lt;p&gt;Reusing our first example, where A = 97:
$$
\begin{aligned}
97-B = 0.2 \times 97
\end{aligned}
$$
So, for symptoms to have improved by at least 20% from a baseline of A
= 97, the symptom score at B should be 77.6 or lower.&lt;/p&gt;
&lt;p&gt;What would this reduction look like in s% (sympercents)?&lt;/p&gt;
&lt;p&gt;If A = 97, and we know a 20% reduction (or 0.2) would represent B = 77.6 then:&lt;/p&gt;
&lt;p&gt;$$
100 × [\ln(97)−\ln(77.6)] ≈ 22.3 s\%
$$&lt;/p&gt;
&lt;h1 id=&#34;references&#34;&gt;References&lt;/h1&gt;
&lt;p&gt;Cole, Tim J, and Douglas G Altman. 2017a. “Statistics Notes: Percentage
Differences, Symmetry, and Natural Logarithms.” &lt;em&gt;BMJ&lt;/em&gt; 358. British
Medical Journal Publishing Group: j3683.&lt;/p&gt;
&lt;p&gt;———. 2017b. “Statistics Notes: What Is a Percentage Difference?” &lt;em&gt;BMJ&lt;/em&gt;
358. British Medical Journal Publishing Group: j3663.&lt;/p&gt;
&lt;p&gt;Cole, TJ. 2000. “Sympercents: Symmetric Percentage Differences on the
100 log&lt;sub&gt;&lt;em&gt;e&lt;/em&gt;&lt;/sub&gt; Scale Simplify the Presentation of Log Transformed
Data.” &lt;em&gt;Statistics in Medicine&lt;/em&gt; 19 (22). Wiley Online Library: 3109–25.&lt;/p&gt;
&lt;p&gt;Howes, Oliver D, Rob McCutcheon, Ofer Agid, Andrea De Bartolomeis, Nico
JM Van Beveren, Michael L Birnbaum, Michael AP Bloomfield, et al. 2016.
“Treatment-Resistant Schizophrenia: Treatment Response and Resistance in
Psychosis (Trrip) Working Group Consensus Guidelines on Diagnosis and
Terminology.” &lt;em&gt;American Journal of Psychiatry&lt;/em&gt; 174 (3). Am Psychiatric
Assoc: 216–29.&lt;/p&gt;
&lt;p&gt;Leucht, S, JM Davis, RR Engel, W Kissling, and JM Kane. 2009.
“Definitions of Response and Remission in Schizophrenia: Recommendations
for Their Use and Their Presentation.” &lt;em&gt;Acta Psychiatrica Scandinavica&lt;/em&gt;
119. Wiley Online Library: 7–14.&lt;/p&gt;
&lt;p&gt;Munk-Jørgensen, Povl. 2011. “Corrigendum.” &lt;em&gt;Acta Psychiatrica
Scandinavica&lt;/em&gt; 124 (1): 82–82.
doi:&lt;a href=&#34;https://doi.org/10.1111/j.1600-0447.2011.01720.x&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;10.1111/j.1600-0447.2011.01720.x&lt;/a&gt;.&lt;/p&gt;
&lt;p&gt;Senn, Stephen S. 2008. &lt;em&gt;Statistical Issues in Drug Development&lt;/em&gt;. Vol.
69. John Wiley &amp;amp; Sons.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
